TherapeuticsMD (NASDAQ:TXMD) Receives New Coverage from Analysts at StockNews.com

Equities research analysts at StockNews.com assumed coverage on shares of TherapeuticsMD (NASDAQ:TXMD) in a report released on Friday. The brokerage set a “hold” rating on the stock.

TherapeuticsMD Trading Up 1.7 %

Shares of NASDAQ:TXMD opened at $1.78 on Friday. The business’s fifty day moving average price is $1.96 and its two-hundred day moving average price is $2.14. TherapeuticsMD has a fifty-two week low of $1.43 and a fifty-two week high of $4.35.

TherapeuticsMD (NASDAQ:TXMD) last announced its earnings results on Friday, May 10th. The company reported ($0.07) EPS for the quarter. The firm had revenue of $0.31 million during the quarter.

Hedge Funds Weigh In On TherapeuticsMD

An institutional investor recently bought a new position in TherapeuticsMD stock. Prosperity Consulting Group LLC bought a new stake in TherapeuticsMD, Inc. (NASDAQ:TXMD) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 24,500 shares of the company’s stock, valued at approximately $56,000. Prosperity Consulting Group LLC owned 0.21% of TherapeuticsMD at the end of the most recent quarter. Institutional investors own 30.74% of the company’s stock.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.